Publication date: Available online 22 January 2016
Source:Bioorganic & Medicinal Chemistry
Author(s): Hiroaki Ohno, Daiki Minamiguchi, Shinya Nakamura, Keito Shu, Shiho Okazaki, Maho Honda, Ryosuke Misu, Hirotomo Moriwaki, Shinsuke Nakanishi, Shinya Oishi, Takayoshi Kinoshita, Isao Nakanishi, Nobutaka Fujii
Two classes of modified analogs of 4-(thiazol-5-yl)benzoic acid-type CK2 inhibitors were designed. The azabenzene analogs, pyridine- and pyridazine-carboxylic acid derivatives, showed potent protein kinase CK2 inhibitory activities [IC50 (CK2α) = 0.014–0.017 μM; IC50 (CK2α') = 0.0046–0.010 μM]. Introduction of a 2-halo- or 2-methoxy-benzyloxy group at the 3-position of the benzoic acid moiety maintained the potent CK2 inhibitory activities [IC50 (CK2α) = 0.014–0.016 μM; IC50 (CK2α') = 0.0088–0.014 μM] and led to antiproliferative activities [CC50 (A549) = 1.5–3.3 μM] three to six times higher than those of the parent compound.
Graphical abstract
from #Medicine via ola Kala on Inoreader http://ift.tt/1Pak2Cq
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.